专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

KR101651304B1 ＨＭＧＢ1 의존적인 ＨＩＶ-1 복제 및 지속감염 촉발의 조절에 의한 인간 면역결핍 바이러스 감염의 모니터링 및 억제 有权
标题翻译： 1 -1通过调节HMGB1依赖性HIV-1复制和持续性触发来监测和抑制人体免疫缺陷病毒感染
公开(公告)号：KR101651304B1
公开(公告)日：2016-08-25
申请号：KR1020117006628
申请日：2009-09-11
申请人： 앵스티띠 파스퇴르
发明人： 구종마리-리즈 , 새디엘라 , 멜키마리아-떼레즈 , 뿌아리에-보도엥베아트리스 , 세페발레리
IPC分类号： G01N33/53 , G01N33/68 , G01N33/569
CPC分类号： G01N33/6875 , A61K31/00 , A61K31/704 , C12N2740/16011 , G01N33/56988 , G01N2333/16 , G01N2333/4703 , G01N2800/52
摘要： 본발명은고 운동성박스 1(HMGB1) 단백질이자연살해(NK) 세포와상호작용하는능력을억제하는물질을포함하는, 인간면역결핍바이러스(HIV) 감염을조절하기위한조성물및 방법을제공한다. 치료조성물은 HMGB1에결합하는항체및 약물, 예컨대글리시리진을포함한다. HIV 감염을검출또는모니터링하는방법은생물학적샘플중 HMGB1 또는 HMGB1 특이적항체의검출또는정량을포함한다.

2. 发明公开

KR1020130094915A 인간 면역 결핍 바이러스의 엔씨와 텟 단백질의 상호작용 및 바이러스 잠복상태 치료제의 표적으로서의 용도 无效
标题翻译：艾滋病病毒与蛋白质之间的相互作用和治疗目标用于其延迟抑制剂的相互作用
公开(公告)号：KR1020130094915A
公开(公告)日：2013-08-27
申请号：KR1020120016176
申请日：2012-02-17
申请人： 한국외국어대학교 연구산학협력단
发明人： 명희준 , 홍혜원
IPC分类号： A61K39/395 , A61K38/16 , A61K38/10 , A61P31/18
CPC分类号： A61K38/00 , A61K39/395 , C12N2740/16011
摘要： PURPOSE: The interaction of NC and Tat is provided to be able to be effectively used as a therapeutic agent target with a purpose of removing the latent state as the interaction causes the Tat reduction, which acts as one factor causing virus latency. CONSTITUTION: The interaction of HIV NC and Tat is provided as an inhibitor target for hindering the latency, based on that the interaction of HIV NC and Tat protein causes the latency. The amount of Tat is reduced by the interaction of HIV NC and Tat protein so that the transcription of HIV is reduced. The transcription level of HIV is controlled according the expression ratio of Tat.
摘要翻译：目的：提供NC和Tat的相互作用，以便能够有效地用作治疗剂靶，目的是消除潜在的状态，因为相互作用导致Tat减少，其作为导致病毒潜伏期的一个因素。构成：HIV NC和Tat的相互作用被提供作为阻碍潜伏期的抑制剂靶标，基于HIV NC和Tat蛋白的相互作用导致潜伏期。通过HIV NC和Tat蛋白的相互作用降低Tat的量，从而减少HIV的转录。根据Tat的表达比例控制HIV的转录水平。

3. 发明公开

KR1020090094380A 감염 및 종양 치료를 위한 조성물 및 방법 有权
标题翻译：用于治疗感染和肿瘤的组合物和方法
公开(公告)号：KR1020090094380A
公开(公告)日：2009-09-04
申请号：KR1020097015114
申请日：2007-12-26
申请人： 에모리 유니버시티 , 다나-파버 캔서 인스티튜트 인크. , 프레지던트 앤드 펠로우즈 오브 하바드 칼리지
发明人： 아메드라피 , 아마라라마 , 프리맨고든 , 샤프알린
IPC分类号： A61K39/395 , A61K39/12 , A61K31/20 , A61P31/12
CPC分类号： C07K16/2827 , A61K39/12 , A61K39/395 , A61K2039/505 , A61K2039/507 , A61K2039/5158 , A61K2039/5256 , C07K16/2818 , C12N2710/24143 , C12N2740/16011 , C12N2760/10011 , C12N2760/10034 , C12N2770/24211 , A61K2300/00
摘要： PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.
摘要翻译：公开了可用于降低受试者中PD-1的表达或活性的PD-1拮抗剂。使用这些PD-1拮抗剂与来自感染剂或肿瘤的抗原可以增强特异于感染剂或肿瘤细胞的免疫应答。因此，可以使用PD-1拮抗剂治疗感染的受试者，例如持续感染。此外，可以使用PD-1拮抗剂治疗具有肿瘤的受试者。在几个实例中，可以通过移植治疗有效量的识别感兴趣的抗原的活化T细胞并通过施用治疗有效量的PD-1拮抗剂来治疗受试者。

4. 发明公开

KR1020090090953A ＡＩＤＳ 예방 및 치료를 위한 ＡＩＤＳＤＮＡ백신(ＧＸ-127) 또는 재조합 아데노바이러스 无效
标题翻译：艾滋病疫苗或重组腺病毒治疗或预防艾滋病
公开(公告)号：KR1020090090953A
公开(公告)日：2009-08-26
申请号：KR1020080016534
申请日：2008-02-22
申请人： 포항공과대학교 산학협력단
发明人： 성영철 , 김광순 , 박기석 , 안소신 , 서유석
IPC分类号： A61K39/235 , A61K39/12 , A61P31/18
CPC分类号： A61K39/235 , A61K38/00 , C12N2740/16011 , C12N2740/16311
摘要： A DNA vaccine composition for preventing and treating AIDS (acquired immunodeficiency syndrome) or a recombinant adenovirus are provided to induce broad immune response. A vaccine composition for treating or preventing HIV (Human immunodeficiency virus) comprises an expression vector containing Gag, Env, Pol antigen gene of HIV B type, and conjugated antigen of regulatory protein or recombinant virus vector. Each N terminal of Env, Pol antigen and Reg gene is conjugated with signal sequence of tissue plasminogen activator (tPA). The Pol antigen gene is substituted to phenyulalanine from tyrosine which is 183th amino acid of removing enzyme activation of reverse transcriptase.
摘要翻译：提供用于预防和治疗AIDS（获得性免疫缺陷综合征）或重组腺病毒的DNA疫苗组合物以诱导广泛的免疫应答。用于治疗或预防HIV（人类免疫缺陷病毒）的疫苗组合物包含含有HIV B型的Gag，Env，Pol抗原基因和调节蛋白或重组病毒载体的共轭抗原的表达载体。 Env，Pol抗原和Reg基因的每个N末端与组织纤溶酶原激活物（tPA）的信号序列缀合。将Pol抗原基因从去除逆转录酶的酶活化的第183位氨基酸的酪氨酸取代为苯丙氨酸。

5. 发明公开

KR1020120125283A ＲＡＮＴＥＳ를 암호화하는 핵산 분자, 그리고 이를 포함하는 조성물 및 이의 사용 방법 有权
标题翻译：编码RANTES的核酸分子和包含其的组合物及其使用方法
公开(公告)号：KR1020120125283A
公开(公告)日：2012-11-14
申请号：KR1020127020794
申请日：2011-02-08
申请人： 더 트러스티스 오브 더 유니버시티 오브 펜실바니아
发明人： 위너,다비드,비. , 보이어,진,디. , 쿠츨러,미쉘
IPC分类号： C12N15/63 , A61K39/12 , A61K39/21 , A61K48/00 , C07K14/52 , A61K39/00
CPC分类号： C07K14/523 , A61K31/7088 , A61K39/12 , A61K39/21 , A61K48/00 , A61K2039/53 , A61K2039/545 , A61K2039/55538 , A61K2039/57 , C07H21/04 , C07K14/435 , C07K14/47 , C12N15/63 , C12N2740/15034 , C12N2740/16011 , C12N2740/16034 , Y02A50/41 , Y02A50/412 , Y02A50/423 , Y02A50/491
摘要： RANTES 및 그의 단편 및 변이체를 암호화하는 뉴클레오타이드 서열을 포함하는 핵산 분자가 제공된다. 추가로, 면역원을 암호화하는 핵산 서열과 조합된 RANTES 및 그의 단편 및 변이체를 암호화하는 뉴클레오타이드 서열을 포함하는 핵산 분자 및 조성물이 제공된다. 면역원을 암호화하는 핵산 서열과 함께 또는 이것 없이, RANTES 및 그의 단편 및 변이체를 암호화하는 뉴클레오타이드 서열을 포함하는 재조합 바이러스 벡터도 또한 RANTES 및 그의 단편 및 변이체를 암호화하는 뉴클레오타이드 서열을 포함하는 약독화 생병원체와 같이 제공된다. 면역 반응의 조절 방법 및 면역원에 대한 면역 반응의 유도 방법도 또한 개시된다.
摘要翻译：公开了包含编码RANTES的核苷酸序列及其片段和变体的核酸分子。此外，提供了包含编码RANTES的核苷酸序列及其片段及其变体与编码免疫原的核酸序列组合的核酸分子和组合物。还提供包含编码RANTES的核苷酸序列的重组病毒载体及其编码免疫原的核酸序列的片段和变体，包括编码RANTES的核苷酸序列及其片段和变体的活减毒病原体。还公开了调节免疫应答和诱导针对免疫原的免疫应答的方法。

6. 发明公开

KR1020100075483A 장산재 핵 요소 폴리펩티드 조성물 및 그것의 사용방법 无效
标题翻译：长度相互关联的元素多肽组合物及其使用方法
公开(公告)号：KR1020100075483A
公开(公告)日：2010-07-02
申请号：KR1020107007557
申请日：2008-09-19
申请人： 더 제이. 데이비드 글래드스톤 인스티튜트 , 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 , 오스트로프스키, 마리오 , 존스, 알. 브레들리
发明人： 닉슨,더글라스 , 개리슨,케이스 , 마이클존,던컨 , 오스트로프스키,마리오 , 존스,알.브레들리 , 아그라왈,아시시 , 헥트,프레데릭엠.
IPC分类号： A61K38/10 , A61K38/08 , A61K48/00 , A61P35/00
CPC分类号： C07K14/47 , A61K39/0005 , A61K39/0011 , A61K2039/53 , A61K2039/55 , A61K2039/57 , C12N2740/16011 , G01N33/5047 , G01N2333/15 , G01N2333/52
摘要： The present invention provides LINE polypeptides; and compositions, including immunogenic compositions, comprising a subject LINE polypeptide. The present invention provides a recombinant nucleic acid comprising a nucleotide sequence encoding a subject LINE polypeptide. A subject composition is useful for stimulating a T-cell immune response to a LINE peptide. The present invention further provides methods of stimulating an immune response in an individual to a retrovirus-or lentivirus-infected cell. The present invention further provides methods of treating cancers that are associated with tissues in which LINE polypeptides are aberrantly expressed. Also provided are methods of treating disorders, involving decreasing an immune response to a LINE polypeptide.
摘要翻译：本发明提供LINE多肽; 和包含免疫原性组合物的组合物，其包含受试者LINE多肽。本发明提供了包含编码受试者LINE多肽的核苷酸序列的重组核酸。主题组合物可用于刺激对LINE肽的T细胞免疫应答。本发明还提供刺激个体对逆转录病毒或慢病毒感染细胞的免疫应答的方法。本发明还提供了治疗与LINE多肽异常表达的组织相关的癌症的方法。还提供了治疗疾病的方法，涉及降低对LINE多肽的免疫应答。

7. 发明公开

KR1020010033062A 렌티바이러스성 벡터의 치료학적 용도 无效
标题翻译：慢病毒载体的治疗用途
公开(公告)号：KR1020010033062A
公开(公告)日：2001-04-25
申请号：KR1020007006423
申请日：1998-12-11
申请人： 낼다이니, 루이기 , 송, 진-핑
发明人： 낼다이니,루이기 , 송,진-핑
IPC分类号： A61K48/00
CPC分类号： A61K35/76 , A61K48/00 , C12N2740/16011
摘要： 본발명은세포중의렌티바이러스의증식을억제하는렌티바이러스성벡터에관한것이다.

8. 发明公开

KR1020030082815A 에이즈 바이러스 유전체의 전사억제제 및 전사억제 방법 无效
标题翻译：艾滋病病毒感染者的代理人和转诊的方法
公开(公告)号：KR1020030082815A
公开(公告)日：2003-10-23
申请号：KR1020020021307
申请日：2002-04-18
申请人： 허만욱
发明人： 허만욱 , 정득림
IPC分类号： C07K19/00
CPC分类号： C07K14/005 , C07K2319/00 , C12N15/62 , C12N2740/16011
摘要： PURPOSE: A repressor for HIV transcription and a method thereof are provided, thereby effectively inhibiting HIV transcription, so that AIDS can be treated. CONSTITUTION: HIV transcription repressing fusion protein of polypeptide having Sp1, NF-κB transcription factor activity repressing or chromatin repressing activity, polypeptide or compound having promoter binding activity, and polypeptide recognizing RNA strand around the expression regulating region or the virus LTR promoter cis-acting region, wherein the polypeptide or compound having Sp1, NF-κB transcription factor activity repressing or chromatin repressing activity is selected from the group consisting of (a) POZ-domain series protein, (b) HDAC or transcription repressing activity region thereof, (c) MeCP2 or MBP series protein, (d) one or more corepressor protein selected from polycom series protein, mSin3A, SMRT, and N-CoR, (e) DNA binding site polypeptide of Sp1, Sp2, Sp3, Sp4 or NF-κB, and (f) a protein capable of binding to the AIDS virus promoter region; the polypeptide or compound recognizing short transcript around the expression regulating region or virus LTR promoter cis-acting region is Tat protein having the amino acid sequence of SEQ ID NO: 1 or 2 or mutant thereof; and the fusion protein is selected from proteins having the amino acid sequences of SEQ ID NOs: 3 to 10.
摘要翻译：目的：提供HIV转录的抑制因子及其方法，从而有效抑制HIV转录，从而可以治疗艾滋病。构成：具有Sp1，NF-κB转录因子活性抑制或染色质抑制活性的多肽的HIV转录抑制融合蛋白，具有启动子结合活性的多肽或化合物和表达调节区周围的多肽识别RNA链或病毒LTR启动子顺式作用区域，其中具有Sp1，NF-κB转录因子活性抑制或染色质抑制活性的多肽或化合物选自（a）POZ结构域序列蛋白，（b）HDAC或其转录抑制活性区，（c ）MeCP2或MBP系列蛋白，（d）选自polycom系列蛋白，mSin3A，SMRT和N-CoR中的一种或多种共抑制因子蛋白，（e）Sp1，Sp2，Sp3，Sp4或NF-κB的DNA结合位点多肽，和（f）能够结合AIDS病毒启动子区的蛋白质; 在表达调节区域或病毒LTR启动子顺式作用区域周围识别短转录物的多肽或化合物是具有SEQ ID NO：1或2或其突变体的氨基酸序列的Tat蛋白质; 并且融合蛋白选自具有SEQ ID NO：3至10的氨基酸序列的蛋白质。

9. 发明公开

KR1020030082191A ＨＩＶ-1의 누클레오캡시드 단백질과 결합할 수 있는 단백질 有权
标题翻译：蛋白质与HIV-1的核酸（NC）蛋白结合
公开(公告)号：KR1020030082191A
公开(公告)日：2003-10-22
申请号：KR1020020020805
申请日：2002-04-17
申请人： 유지창 , 명희준
发明人： 유지창 , 명희준
IPC分类号： C07K14/16
CPC分类号： C07K14/005 , C12N2740/16011
摘要： PURPOSE: Proteins for binding to nucleocapsid(NC) protein of HIV-1 are provided, thereby effectively inhibiting the growth of HIV-1. CONSTITUTION: A peptide pep A having the amino acid sequence of SEQ ID NO: 1 specifically binds to nucleocapsid(NC) protein of HIV-1. A peptide pep B having the amino acid sequence of SEQ ID NO: 2 specifically binds to nucleocapsid(NC) protein of HIV-1. A peptide pep C having the amino acid sequence of SEQ ID NO: 3 specifically binds to nucleocapsid(NC) protein of HIV-1. A peptide pep 1 having the amino acid sequence of SEQ ID NO: 11 specifically binds to nucleocapsid(NC) protein of HIV-1. A peptide pep 2 having the amino acid sequence of SEQ ID NO: 12 specifically binds to nucleocapsid(NC) protein of HIV-1. A peptide pep 3 having the amino acid sequence of SEQ ID NO: 13 specifically binds to nucleocapsid(NC) protein of HIV-1.
摘要翻译：目的：提供与HIV-1核衣壳（NC）蛋白结合的蛋白质，从而有效抑制HIV-1的生长。构成：具有SEQ ID NO：1的氨基酸序列的肽肽A特异性结合HIV-1的核衣壳（NC）蛋白。具有SEQ ID NO：2的氨基酸序列的肽肽B特异性结合HIV-1的核衣壳（NC）蛋白。具有SEQ ID NO：3的氨基酸序列的肽肽C特异性结合HIV-1的核衣壳（NC）蛋白。具有SEQ ID NO：11的氨基酸序列的肽肽1特异性结合HIV-1的核衣壳（NC）蛋白。具有SEQ ID NO：12的氨基酸序列的肽肽2特异性结合HIV-1的核衣壳（NC）蛋白。具有SEQ ID NO：13的氨基酸序列的肽pep 3特异性结合HIV-1的核衣壳（NC）蛋白。

10. 发明公开

KR1020030060274A 인간 면역 결핍 바이러스-1, -2 타입의 단백질이 융합된 재조합 콤보 단백질, 이의 생산방법, 이를 포함하는 벡터, 형질전환된 대장균 및 진단키트 有权
标题翻译：与HIV-1，-2和0蛋白融合的重组蛋白质蛋白质，其制造方法，含有其的转录物及其变体，其诊断试剂盒及其组合物
公开(公告)号：KR1020030060274A
公开(公告)日：2003-07-16
申请号：KR1020020000896
申请日：2002-01-08
申请人： 주식회사 엘지생명과학
发明人： 손미진 , 김은경 , 유승범 , 김형철 , 이상익 , 오재훈
IPC分类号： C07K19/00
CPC分类号： C07K14/005 , C07K2319/00 , C07K2319/21 , C12N15/70 , C12N2740/16011 , G01N33/56988 , G01N2333/16
摘要： PURPOSE: A recombinant combo protein fused with HIV type-1, -2 and 0 proteins, a manufacturing method thereof, a vector containing the same and a transformant thereof, a diagnostic kit thereof and a composition for vaccine thereof are provided. The recombinant combo protein has improved HIV antibody sensitivity and specificity. CONSTITUTION: A single stranded polypeptide fusion protein includes entire or a part of HIV type-1 p24 or gp41, HIV type-2 gp36, HIV type-1 group 0 gp41, wherein the HIV type-1 p24 protein contains entire or a part of the amino acid sequence of SEQ ID NO: 7; the HIV type-1 gp41 protein contains entire or a part of the amino acid sequence of SEQ ID NO: 8; the HIV type-2 gp36 protein contains entire or a part of the amino acid sequence of SEQ ID NO: 9; the HIV type-1 group 0 gp41 protein contains entire or a part of the amino acid sequence of SEQ ID NO: 10; and six-repeated histidine residue is positioned at the C-terminal of the fusion protein. An expression vector pLCSK-1 contains the fusion protein gene. A transformed E. coli(KCTC 10100BP) is produced by transformation with the expression vector pLCSK-1.
摘要翻译：目的：提供与HIV-1，-2和0蛋白融合的重组组合蛋白，其制备方法，含有该蛋白的载体及其转化体，其诊断试剂盒和疫苗组合物。重组组合蛋白具有改善的HIV抗体敏感性和特异性。构成：单链多肽融合蛋白包括HIV-1型p24或gp41，HIV-2型gp36，HIV-1型0Gp41组的全部或部分，其中HIV-1型p24蛋白含有全部或部分 SEQ ID NO：7的氨基酸序列; HIV-1型gp41蛋白含有SEQ ID NO：8的全部或部分氨基酸序列; HIV-2型gp36蛋白含有SEQ ID NO：9的全部或部分氨基酸序列; HIV 1型组0gp41蛋白含有SEQ ID NO：10的全部或部分氨基酸序列; 并且六重组氨酸残基位于融合蛋白的C末端。表达载体pLCSK-1含有融合蛋白基因。通过用表达载体pLCSK-1转化产生转化的大肠杆菌（KCTC 10100BP）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式